<DOC>
	<DOC>NCT00092196</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.</brief_summary>
	<brief_title>Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Patient with a diagnosis of breast cancer requiring treatment with noncisplatin moderately emetogenic chemotherapy. Patient must have completed participation in the main study for this protocol. Patient has a central nervous system malignancy. Patient will receive radiation to the abdomen or pelvis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chemotherapy-Induced Nausea and Vomiting</keyword>
</DOC>